keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable stent

keyword
https://www.readbyqxmd.com/read/29235306/comparison-of-everolimus-eluting-bioresorbable-vascular-scaffolds-and-metallic-stents-three-year-clinical-outcomes-from-the-absorb-china-randomised-trial
#1
Bo Xu, Yuejin Yang, Yaling Han, Yong Huo, Lefeng Wang, Xiangqian Qi, Jifu Li, Yundai Chen, Hai-Chien Kuo, Shih-Wa Ying, Wai-Fung Cheong, Yunlong Zhang, Xiaolu Su, Jeffery Popma, Runlin Gao, Gregg Stone
Aims: Absorb bioresorbable vascular scaffolds (BVS) and XIENCE cobalt-chromium everolimus-eluting stents (CoCr-EES) had comparable angiographic and clinical outcomes up to one year in patients enrolled in the ABSORB China randomised trial. Whether these favourable results with BVS continue beyond one year up to three years is unknown. In this study we sought to analyse the outcomes from the trial up to three-year follow-up. Methods and results: ABSORB China was a prospective, open-label, multicentre trial in which 480 patients with one or two native coronary artery lesions were randomised 1:1 to BVS (N=241) vs...
October 22, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29216997/the-state-of-the-absorb-bioresorbable%C3%A2-scaffold-consensus-from-an-expert-panel
#2
REVIEW
Sripal Bangalore, Hiram G Bezerra, David G Rizik, Ehrin J Armstrong, Bruce Samuels, Srihari S Naidu, Cindy L Grines, Malcolm T Foster, James W Choi, Barry D Bertolet, Atman P Shah, Rebecca Torguson, Surendra B Avula, John C Wang, James P Zidar, Aziz Maksoud, Arun Kalyanasundaram, Steven J Yakubov, Bassem M Chehab, Anthony J Spaedy, Srini P Potluri, Ronald P Caputo, Ashok Kondur, Robert F Merritt, Amir Kaki, Ramon Quesada, Manish A Parikh, Catalin Toma, Fadi Matar, Joseph DeGregorio, William Nicholson, Wayne Batchelor, Raghava Gollapudi, Ethan Korngold, Riyaz Sumar, George S Chrysant, Jun Li, John B Gordon, Rajesh M Dave, Guilherme F Attizzani, Tom P Stys, Osvaldo S Gigliotti, Bruce E Murphy, Stephen G Ellis, Ron Waksman
Significant progress has been made in the percutaneous coronary intervention technique from the days of balloon angioplasty to modern-day metallic drug-eluting stents (DES). Although metallic stents solve a temporary problem of acute recoil following balloon angioplasty, they leave behind a permanent problem implicated in very late events (in addition to neoatherosclerosis). BRS were developed as a potential solution to this permanent problem, but the promise of these devices has been tempered by clinical trials showing increased risk of safety outcomes, both early and late...
December 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29203070/a-sirolimus-eluting-bioabsorbable-polymer-coated-stent-mistent-versus-an-everolimus-eluting-durable-polymer-stent-xience-after-percutaneous-coronary-intervention-dessolve-iii-a-randomised-single-blind-multicentre-non-inferiority-phase-3-trial
#3
Robbert J de Winter, Yuki Katagiri, Taku Asano, Krzysztof P Milewski, Philipp Lurz, Pawel Buszman, Gillian A J Jessurun, Karel T Koch, Roland P T Troquay, Bas J B Hamer, Ton Oude Ophuis, Jochen Wöhrle, Rafał Wyderka, Guillaume Cayla, Sjoerd H Hofma, Sébastien Levesque, Aleksander Żurakowski, Dieter Fischer, Maciej Kośmider, Pascal Goube, E Karin Arkenbout, Michel Noutsias, Markus W Ferrari, Yoshinobu Onuma, William Wijns, Patrick W Serruys
BACKGROUND: MiStent is a drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall. It was developed to overcome the limitation of current durable polymer drug-eluting stents eluting amorphous sirolimus. The clinical effect of MiStent sirolimus-eluting stent compared with a durable polymer drug-eluting stents has not been investigated in a large randomised trial in an all-comer population. METHODS: We did a randomised, single-blind, multicentre, phase 3 study (DESSOLVE III) at 20 hospitals in Germany, France, Netherlands, and Poland...
December 1, 2017: Lancet
https://www.readbyqxmd.com/read/29199861/stenting-the-complex-patent-ductus-arteriosus-in-tetralogy-of-fallot-with-pulmonary-atresia-challenges-and-outcomes
#4
Rizwan Rehman, Mood Che Marhisham, Mazeni Alwi
Patent ductus arteriosus (PDA) stenting has gained acceptance for palliation in cyanotic congenital heart disease. The PDA in tetralogy of Fallot with pulmonary atresia (ToF-PA) arises, in the left aortic arch, from underneath the arch and connects to the proximal left pulmonary artery, often resulting in stenosis. The PDA is usually elongated and tortuous, making stent implantation challenging. Shorter duration of palliation, aggravation of branch pulmonary artery stenosis resulting in poor growth and difficulty at surgery makes ductal stenting controversial...
December 4, 2017: Future Cardiology
https://www.readbyqxmd.com/read/29180778/the-development-of-bioresorbable-composite-polymeric-implants-with-high-mechanical-strength
#5
Upma Sharma, Danny Concagh, Lee Core, Yina Kuang, Changcheng You, Quynh Pham, Greg Zugates, Rany Busold, Stephanie Webber, Jonathan Merlo, Robert Langer, George M Whitesides, Maria Palasis
Implants for the treatment of tissue defects should mimic the mechanical properties of the native tissue of interest and should be resorbable as well as biocompatible. In this work, we developed a scaffold from variants of poly(glycolic) acid which were braided and coated with an elastomer of poly(glycolide-co-caprolactone) and crosslinked. The coating of the scaffold with the elastomer led to higher mechanical strength in terms of compression, expansion and elasticity compared to braids without the elastomer coating...
November 20, 2017: Nature Materials
https://www.readbyqxmd.com/read/29171715/restenosis-patterns-after-bioresorbable-vascular-scaffold-implantation-angiographic-substudy-of-the-ghost-eu-registry
#6
Moritz Baquet, Holger Nef, Tomasso Gori, Azeem Latib, Davide Capodanno, Carlo Di Mario, Manel Sabate, Antonio Colombo, Corrado Tamburino, Julinda Mehilli
OBJECTIVES: To evaluate pattern of in-BVS-restenosis after bioresorbable vascular scaffold (BVS) implantation. BACKGROUND: In-stent restenosis morphology impacts target lesion revascularization (TLR) rates and clinical outcomes. Although several trials report on outcomes after BVS implantation, information about in-BVS restenosis pattern is still lacking. METHODS: Between November 2011 and January 2014, in 7 of 10 European centers participating in the GHOST-EU registry, 668 patients underwent BVS implantation...
November 24, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29171214/bioresorbable-vascular-scaffold-korean-expert-panel-report
#7
REVIEW
Jung Min Ahn, Duk Woo Park, Sung Jin Hong, Young Keun Ahn, Joo Yong Hahn, Won Jang Kim, Soon Jun Hong, Chang Wook Nam, Do Yoon Kang, Seung Yul Lee, Woo Jung Chun, Jung Ho Heo, Deok Kyu Cho, Jin Won Kim, Sung Ho Her, Sang Wook Kim, Sang Yong Yoo, Myeong Ki Hong, Seung Jea Tahk, Kee Sik Kim, Moo Hyun Kim, Yangsoo Jang, Seung Jung Park
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea...
November 6, 2017: Korean Circulation Journal
https://www.readbyqxmd.com/read/29168541/evaluation-of-bioresorbable-vascular-scaffolds-in-acute-coronary-syndrome-a-two-center-one-year-follow-up-analysis
#8
Sylwia Iwańczyk, Jarosław Hiczkiewicz, Aleksander Araszkiewicz, Magdalena Łanocha, Daria Adamczak, Wojciech Faron, Stefan Grajek, Maciej Lesiak
BACKGROUND: Bioresorbable vascular scaffolds (BVS) have emerged as a new treatment option in cardiovascular medicine. Nonetheless, there is still limited data on the use of these novel devices in patients with acute coronary syndromes (ACS). The purpose of this study was to evaluate the feasibility and efficacy of BVS implantation in patients with ACS. METHODS: The present report is a prospective, two-centre registry that involved 165 consecutive patients hospitalized with the diagnosis of ACS and treated with the Absorb BVS (Abbot Vascular, Santa Clara, USA)...
November 23, 2017: Cardiology Journal
https://www.readbyqxmd.com/read/29167623/bioresorbable-vascular-scaffold-stent-delivered-to-tortuous-lesions-by-using-the-five-in-six-system
#9
Wen-Jung Chung, Hsiu-Yu Fang, Chiung-Jen Wu
A 5Fr ST01, which is a straight-tip guiding catheter with an inner lumen of 1.5 mm, is frequently used to perform the "child-in-mother" technique, which is also referred to as the "5-in-6" technique. A 6Fr or larger size guiding catheter can facilitate bioresorbable everolimus-eluting vascular scaffold (BVS) delivery. For tortuous lesions, the 5-in-6 technique can facilitate balloon catheters and the BVS in crossing tortuous lesions by increasing the back-up support. However, this maneuver couldn't be used for the larger size of BVS like 3...
November 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/29166699/comparison-of-clinical-outcomes-of-coronary-artery-stent-implantation-in-patients-with-end-stage-chronic-kidney-disease-including-hemodialysis-for-three-everolimus-eluting-ees-stent-designs-bioresorbable-polymer-ees-platinum-chromium-ees-and-cobalt-chrome-ees
#10
Takao Sato, Katsuharu Hatada, Syohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Minoru Takahashi, Taku Matsubara, Masaaki Okabe, Yoshifusa Aizawa
BACKGROUNDS: New-generation bioresorbable polymer-everolimus eluting stents (BP-EES) are available. This study aimed to compare the clinical outcomes for BP-EES compared to more established stent designs, namely the platinum chromium-EES (PtCr-EES) and cobalt chrome-EES(CoCr-EES) in patients with the end-stage chronic kidney disease (CKD) including hemodialysis (HD). METHODS: One-hundred-forty-one consecutive stents (BP-EES [n = 44], PtCr-EES [n = 45], and CoCr-EES [n = 52]) were implanted in 104 patients with CKD...
November 22, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/29160048/from-biodegradable-polymers-to-bioresorbable-vascular-scaffolds-available-evidence-in-the-current-era-of-new-generation-des
#11
Fabio Magliulo, Raffaele Piccolo, Anna Franzone, Giovanni Esposito, Gian B Danzi
New-generation drug-eluting stents (DES) encompass a large variety of coronary devices, featuring thin struts, biocompatible durable or biodegradable polymer coatings, and limus-eluting drugs. Due to improved early and long-term outcomes among patients undergoing percutaneous coronary intervention, new-generation metallic DES are recommended in almost all patient and lesion subsets. Available evidence from randomized trials indicate a similar safety and efficacy profile between biodegradable and durable polymers new-generation DES...
November 20, 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29148244/real-life-experience-with-bioresorbable-polymer-everolimus-eluting-stents-is-this-an-answer-in-search-of-a-question
#12
EDITORIAL
Youssef Rahban, Carey Kimmelstiel
Stent thrombosis and clinically driven restenosis are rare in the era of newer generation DES. The Synergy bioresorbable polymer DES appears to be comparable to other durable polymer and other bioabsorbable polymer DES in terms of safety and efficacy at 1-year post implantation. Further long-term study is needed to determine the specific role of the Synergy stent and other DES with bioabsorbable polymers.
November 15, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29147473/bioresorbable-vascular-scaffold-versus-metallic-stent-in-percutaneous-coronary-intervention-results-of-the-aida-trial
#13
Syed Raza Shah, Mazia Fatima, Amin Muhammad Dharani, Waqas Shahnawaz, Syed Arbab Shah
Drug-eluting stents have significantly improved the long-term outcomes of percutaneous coronary intervention (PCI) by decreasing the excessive growth of neointima. However, conventional stents have some limitations. PCI with a bioresorbable vascular scaffold (BVS) has emerged as an alternative since the presence of the prosthesis in the coronary artery is transient. A US Food and Drug Administration advisory panel of experts recommended approval of BVS based on the analysis of its risks and rewards in July 2016...
2017: Journal of Community Hospital Internal Medicine Perspectives
https://www.readbyqxmd.com/read/29131802/acute-and-one-year-clinical-outcomes-following-implantation-of-bioresorbable-vascular-scaffolds-the-absorb-uk-registry
#14
Andreas Baumbach, Azfar Zaman, Nick Ej West, Peter O'Kane, Mohaned Egred, Thomas Johnson, Stephen Wheatcroft, Bowles Ruth, Adam de Belder, Georgious Bouras, Alexandra Lansky, Jonathan Hill, Anthony Mathur, Mark A de Belder, Adrian Banning
AIMS: The aim was to monitor practice patterns and outcomes in patients treated with Absorb bioresorbable vascular scaffolds (BVS) during the early phase of usage in the UK. METHODS AND RESULTS: A total of 1005 patients with de-novo coronary lesions were treated using careful implantation techniques at 24 centers. Follow-up at one year was obtained in 99%. An independent clinical event committee and angiographic corelab adjudicated all events. Patient age was 52 years and 46% presented with acute coronary syndromes...
November 14, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29131799/multi-slice-computed-tomography-assessment-of-everolimus-eluting-absorb-bioresorbable-scaffold-in-comparison-with-metallic-drug-eluting-stents-from-the-absorb-japan-randomized-trial
#15
Kengo Tanabe, Jeffrey J Popma, Ken Kozuma, Shigeru Saito, Toshiya Muramatsu, Sunao Nakamura, Atsuo Namiki, Yoshihiro Morino, Nobuhisa Hagiwara, Masaaki Uematsu, Tomohiro Kawasaki, Kenshi Fujii, Patrick W Serruys, Yoshinobu Onuma, Shihwa Ying, Hajime Kusano, Gregg W Stone, Takeshi Kimura
AIMS: Blooming artifacts limit accurate coronary assessment by multi-slice computed tomography (MSCT) in metallic stents. We sought to investigate whether bioresorbable vascular scaffold (BVS) could be better assessed by MSCT. Methods and Results: Among 400 patients in the randomized ABSORB Japan trial, a pre-specified MSCT sub-study was performed in 98 patients (103 lesions) in the BVS arm and 49 patients (49 lesions) in the cobalt chromium everolimus-eluting stent (CoCr-EES) arm at 13-month prior to follow-up angiography...
November 14, 2017: EuroIntervention
https://www.readbyqxmd.com/read/29129253/rationale-of-a-novel-study-design-for-the-bioflow-v-study-a-prospective-randomized-multicenter-study-to-assess-the-safety-and-efficacy-of-the-orsiro-sirolimus-eluting-coronary-stent-system-using-a-bayesian-approach
#16
Gheorghe Doros, Joseph M Massaro, David E Kandzari, Ron Waksman, Jacques J Koolen, Donald E Cutlip, Laura Mauri
BACKGROUND: Traditional study design submitted to the Food and Drug Administration to test newer drug-eluting stents (DES) for marketing approval is the prospective randomized controlled trial. However, several DES have extensive clinical data from trials conducted outside the United States that have led to utilization of a novel design using the Bayesian approach. This design was proposed for testing DES with bioresorbable polymer compared with DES most commonly in use today that use durable polymers for drug elution...
November 2017: American Heart Journal
https://www.readbyqxmd.com/read/29108400/early-experience-and-favorable-clinical-outcomes-of-everolimus-eluting-bioresorbable-scaffolds-for-coronary-artery-disease-in-korea
#17
Osung Kwon, Jung-Min Ahn, Do-Yoon Kang, Se Hun Kang, Pil Hyung Lee, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Duk-Woo Park, Seung-Jung Park
Background/Aims: Compared with metallic drug-eluting stents (DES), bioresorbable vascular scaffolds (BVS) may further improve long-term outcomes of percutaneous coronary intervention (PCI) in patients with coronary artery disease. We report our early experience with BVS in Korea. Methods: We evaluated 105 consecutive patients with BVS implanted at Asan Medical Center, Korea between October 21, 2015 and June 3, 2016. Angiographic results, and in-hospital and 6-month clinical outcomes were assessed...
November 7, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29106830/-contribution-of-intracoronary-imaging-in-acute-coronary-syndrome
#18
A Rougé, J Wintzer-Wehekind, S Milouchi, M Abdellaoui, B Faurie, J Monségu
Acute coronary syndrome (ACS) remains a major cause of mortality and morbidity in the world, although it has considerably decreased through technical and pharmacological advances. The physiopathological approach of the ACS has progressed considerably in recent years thanks to the anatomopathological work and the data of the endocoronary imaging, in particular of the endovascular ultrasound (IVUS). Plaque rupture is the most common cause of ACS, however OCT (optical coherence tomography) studies have shown that surface plaque erosion was more common than thought...
October 26, 2017: Annales de Cardiologie et D'angéiologie
https://www.readbyqxmd.com/read/29100702/3-year-clinical-outcomes-with-everolimus-eluting-bioresorbable-coronary-scaffolds-the%C3%A2-absorb-iii-trial
#19
Dean J Kereiakes, Stephen G Ellis, Christopher Metzger, Ronald P Caputo, David G Rizik, Paul S Teirstein, Marc R Litt, Annapoorna Kini, Ameer Kabour, Steven O Marx, Jeffrey J Popma, Robert McGreevy, Zhen Zhang, Charles Simonton, Gregg W Stone
BACKGROUND: The Absorb everolimus-eluting poly-L-lactic acid-based bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support functions similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximately 3 years with recovery of vascular structure and function. The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI], or ischemia-driven target lesion revascularization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-chromium everolimus-eluting stents (EES)...
October 20, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29096803/mechanisms-of-very-late-bioresorbable%C3%A2-scaffold-thrombosis-the-invest-registry
#20
Kyohei Yamaji, Yasushi Ueki, Geraud Souteyrand, Joost Daemen, Jens Wiebe, Holger Nef, Tom Adriaenssens, Joshua P Loh, Benoit Lattuca, Joanna J Wykrzykowska, Josep Gomez-Lara, Leo Timmers, Pascal Motreff, Petra Hoppmann, Mohamed Abdel-Wahab, Robert A Byrne, Felix Meincke, Niklas Boeder, Benjamin Honton, Crochan J O'Sullivan, Alfonso Ielasi, Nicolas Delarche, Günter Christ, Joe K T Lee, Michael Lee, Nicolas Amabile, Alexios Karagiannis, Stephan Windecker, Lorenz Räber
BACKGROUND: Very late scaffold thrombosis (VLScT) occurs more frequently after bioresorbable scaffold (Absorb BVS 1.1, Abbott Vascular, Santa Clara, California) implantation than with metallic everolimus-eluting stents. OBJECTIVES: The purpose of this study was to elucidate mechanisms underlying VLScT as assessed by optical coherence tomography (OCT). METHODS: The INVEST (Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis) registry is an international consortium of investigators who used OCT to examine patients with VLScT...
November 7, 2017: Journal of the American College of Cardiology
keyword
keyword
116611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"